Insulet Corporation (NASDAQ:PODD) is a medical device company that develops and manufactures the Omnipod insulin-delivery system. On August 5, 2026, the investment firm Oppenheimer downgraded its rating on Insulet Corporation. The firm changed its grade from Outperform to Perform when the stock price was $132.34.
The stock downgrade coincided with the release of the company's second-quarter earnings, as highlighted by Seeking Alpha. Insulet Corporation announced a 23% revenue growth on a constant-currency basis, generating $802 million. This increase was fueled by strong demand for its Omnipod system in both U.S. and international markets.
Despite the strong quarterly performance, the company adjusted its future outlook. While international Omnipod revenue increased by 35%, Insulet Corporation lowered its full-year 2026 revenue growth expectations for its U.S. and total company operations. This revised guidance likely contributed to the rating change from Oppenheimer.
Financially, the company's profitability metrics improved. Adjusted earnings per share, which measures a company's profit for each share of its stock, climbed 41.5% to $1.66. The adjusted gross margin expanded to 72.9%, and the adjusted operating margin, which shows profit from core business, increased to 19.3%.
The market reacted negatively to the news. The stock price for Insulet Corporation fell by 20.82% to $132.08, reaching a new 52-week low of $126.50 during the day. The company has a market capitalization of about $9.15 billion, with a daily trading volume of around 5.45 million shares.
